Roivant Sciences (Nasdaq: ROIV) announced that the U.S. Food and Drug Administration has approved LISRAYA (brepocitinib) 30 mg, a once-daily ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA